Rosa Biotech secures £415,000 to accelerate early disease screening

Posted by 

SETsquared Bristol

Bio-sensing pioneer Rosa Biotech has secured £415,000 from angel investors and announced plans to accelerate development of its bio-sensing technology, designed to enable cost effective, early-stage screening of a range of life-threatening diseases.

Three Rosa Biotech scientists in lab looking at samplesThe University of Bristol healthtech spinout joined SETsquared Bristol in February 2023. It is initially targeting the early identification of non-alcoholic fatty liver disease (NAFL) which, if left untreated can develop into steatohepatitis (NASH) leading to liver failure. The Western world has experienced a 100% increase in NASH cases during the last 30 years and this trend is expected to accelerate in the coming decades.

Rosa’s Pandra platform combines patented synthetic biology with sophisticated machine learning, and is particularly suited to the detection at scale of a range of life-threatening diseases with high accuracy in patient blood samples. The company is currently collaborating with scientists, clinicians and industry to further develop and validate Pandra and bring its first tests into the clinic.

The £415,000 seed+ investment comes from a group of experienced technology and life sciences entrepreneurs, and builds upon substantial investment that has already been deployed by the business. It will allow Rosa to accelerate pre-clinical NAFLD/NASH trials, and provides a bridge to Series A funding, planned for later this year, targeting full commercialisation of Rosa’s NAFLD/NASH offering.

The pre-clinical evaluations will use samples from The National Institute for Health and Care Research BioResource, the British government’s major funder of clinical, public health, social care and translational research, and University Hospitals of Coventry and Warwick NHS Trust.

Dr Mark Street-Docherty, CEO of Rosa Biotech, said:

“The prevalence of NAFLD is increasing at an alarming rate, placing an ever growing burden on specialist healthcare resources. With over 100 therapeutic interventions in clinical development, it’s critical that healthcare providers can cost effectively screen for early signs of this condition, enabling treatment and lifestyle changes to occur early enough to prevent permanent liver damage and failure.

With Series A funding expected to follow later in the year, this is an incredibly exciting time for our business. Pandra technology is moving ever closer to commercialisation, and will enable Rosa Biotech to save lives and help protect vital healthcare infrastructure.”

Recent News, Blogs and Stories

Hot air balloon over Clifton Suspension Bridge

SETsquared Bristol’s guide to regional business support resources

We understand that it’s tough starting out with a new startup, so we've put together this guide to the business support services we offer, as well as other options available...
Kailash Manohara Selvan from SpatialCortex with Jack Jordan Connelly at SETsquared Investment Futures event

Bristol startups pitch at SETsquared’s 20th annual investment event

Six of our companies were selected to present their startups at SETsquared’s Investment Futures 24 showcase in London this November. Investment Futures is an annual high-profile occasion that over its...
Impulsonics founders at NEC competition

Biotech startup Impulsonics awarded £300,000 Innovate UK grant

Bristol-based startup, Impulsonics has been awarded the prestigious ICURe spinout support grant of £300,000 to enable the development of its unique technology platform for biotech automation. The grant will enable...


Fast track your technology business